ClinicalTrials.gg
RecruitingNCT07792408Updated Sep 30, 2026

Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

A Phase 1 interventional study of VX-407 and LNG/EE in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated. Recruiting at 1 site in Canada. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Sep 30, 2026Now RecruitingFirst site in Canada+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
148
Allocation
Non-randomized
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Canada — 3 open to participants now, 6 under way, none of them phase 3. Polycystic Kidney, Autosomal Dominant · Canada.

Planned enrollment
9th of 12
148 · median 206
Started
2026
the only one that year
Phase 1
3 of 16
1 open now
Registered
16th of 16
by date
Lead sponsor
4 of 16
Vertex Pharmaceuticals Incorporated

Among the 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Canada, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 3 in phase 1, and was the 16th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

3 of the 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Canada are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Polycystic Kidney, Autosomal Dominant with a site in Canada, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives.

Read the detailed description

The purpose of the study is to evaluate the pharmacokinetic effects and safety and tolerability of VX-407 when coadministered with oral contraceptives. This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m\^2), inclusive
  • A total body weight of greater than (>) 50 kg

Key Exclusion Criteria:

  • History of febrile illness within 5 days before the first dose of study drug
  • Pregnant, nursing, or planning to become pregnant during the study or within 90 days after the last dose of study drug

Other protocol defined Inclusion/Exclusion criteria will apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
148 participants (estimated)

Study arms

  • Experimental
    Part A: VX-407 With Levonorgestrel/Ethinyl Estradiol (LNG/EE)

    Participants will receive a single dose of LNG/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 every 12 hours (q12h) from Days 8 through 26 in fasted state.

    Drug: VX-407 · Drug: LNG/EE

  • Experimental
    Part B (Optional): VX-407 With Norgestimate/Ethinyl Estradiol (NGM/EE)

    Participants will receive a single dose of NGM/EE on Days 1 and 23 in fasted state. Participants will also receive VX-407 q12h from Days 10 through 30 in fasted state.

    Drug: VX-407 · Drug: NGM/EE

  • Experimental
    Part C (Optional): VX-407 With Norethindrone/Ethinyl Estradiol (NET/EE)

    Participants will receive a single dose of NET/EE on Days 1 and 19 in fasted state. Participants will also receive VX-407 q12h from Days 6 through 22 in fasted state.

    Drug: VX-407 · Drug: NET/EE

  • Experimental
    Part D (Optional): VX-407 With Drospirenone/Ethinyl Estradiol (DRSP/EE)

    Participants will receive a single dose of DRSP/EE on Days 1 and 21 in fasted state. Participants will also receive VX-407 q12h from Days 8 through 26 in fasted state.

    Drug: VX-407 · Drug: DRSP/EE

Interventions

  • DrugVX-407

    Tablets for Oral Administration.

  • DrugLNG/EE

    Combination Tablets for Oral Administration.

  • DrugNGM/EE

    Combination Tablets for Oral Administration.

  • DrugNET/EE

    Combination Tablets for Oral Administration.

  • DrugDRSP/EE

    Drug page: Drospirenone

    Combination Tablets for Oral Administration.

06

What researchers measure

Primary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of LNG/EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  2. Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31

  3. Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of NET and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23

  4. Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of DRSP and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  5. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of LNG/EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

  6. Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of norelgestromin (NGMN) and norgestrel (NG) (active metabolites of NGM) and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 9 and Day 23 up to Day 31

  7. Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of NET and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 5 and Day 19 up to Day 23

  8. Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of DRSP and EE in the Absence and Presence of VX-407

    Time frame: From Day 1 up to Day 7 and Day 21 up to Day 27

Secondary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 36

  2. Part B (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 Up to Day 39

  3. Part C (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 32

  4. Part D (Optional): Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 36

  5. Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  6. Part B (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: Days 11, 17 and 23 up to Day 31

  7. Part C (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: Days 7, 13 and 19 up to Day 23

  8. Part D (Optional): Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  9. Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

  10. Part B (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407

    Time frame: Days 11, 17 and 23 up to Day 31

  11. Part C (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407

    Time frame: Days 7, 13 and 19 up to Day 23

  12. Part D (Optional): Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407

    Time frame: Days 9, 15 and 21 up to Day 27

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/our-science/clinical-trials-data-sharing/

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Sep 2026 (actual). Primary completion is estimated for Mar 2027, 6 months after the start.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Sep 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2026
First posted
Aug 28, 2026
StartActual
Sep 1, 2026was Aug 2026
Primary completionEst.
Mar 11, 2027
CompletionEst.
Mar 20, 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Sep 30, 2026
Sites
1 site added — first site in Canada
Show site
  • Altasciences - Beaumont Clinic Montreal · Montreal, Canada
Sep 30, 2026
Start date
Aug 28, 2026→Sep 1, 2026 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Canada
    Show site
    • Altasciences - Beaumont Clinic Montreal · Montreal, Canada
    Start date Aug 28, 2026→Sep 1, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07792408
Responsible party
Sponsor
First posted
Aug 28, 2026
Start date
Sep 1, 2026
Primary completion
Mar 11, 2027 (estimated)
Completion
Mar 20, 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Medical Information
Contact
medicalinfo@vrtx.com
617-341-6777

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-407

Start the discussion